Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eg sa-nv - bortezomib mannitol boronic ester - eq. bortezomib 2,5 mg/ml - solution for injection - 2,5 mg/ml - bortezomib mannitol boronic ester - bortezomib

European Union - English - EMA (European Medicines Agency)

fresenius kabi deutschland gmbh - bortezomib - multiple myeloma - antineoplastic agents - bortezomib as monotherapy or in combination with pegylated liposomal doxorubicin or dexamethasone is indicated for the treatment of adult patients with progressive multiple myeloma who have received at least 1 prior therapy and who have already undergone or are unsuitable for haematopoietic stem cell transplantation.bortezomib in combination with melphalan and prednisone is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for high-dose chemotherapy with haematopoietic stem cell transplantation.bortezomib in combination with dexamethasone, or with dexamethasone and thalidomide, is indicated for the induction treatment of adult patients with previously untreated multiple myeloma who are eligible for high-dose chemotherapy with haematopoietic stem cell transplantation.bortezomib in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma who are unsuitable for haematopoietic stem cell transplantation.

Canada - English - Health Canada

marcan pharmaceuticals inc - bortezomib (bortezomib mannitol boronic ester) - powder for solution - 3.5mg - bortezomib (bortezomib mannitol boronic ester) 3.5mg - antineoplastic agents

Canada - English - Health Canada

juno pharmaceuticals corp. - bortezomib (bortezomib mannitol boronic ester) - powder for solution - 1mg - bortezomib (bortezomib mannitol boronic ester) 1mg - antineoplastic agents

Canada - English - Health Canada

juno pharmaceuticals corp. - bortezomib (bortezomib mannitol boronic ester) - powder for solution - 2.5mg - bortezomib (bortezomib mannitol boronic ester) 2.5mg - antineoplastic agents

Canada - English - Health Canada

taro pharmaceuticals inc - bortezomib (bortezomib mannitol boronic ester) - powder for solution - 3.5mg - bortezomib (bortezomib mannitol boronic ester) 3.5mg - antineoplastic agents

Canada - English - Health Canada

auro pharma inc - bortezomib (bortezomib mannitol boronic ester) - powder for solution - 3.5mg - bortezomib (bortezomib mannitol boronic ester) 3.5mg - antineoplastic agents

Canada - English - Health Canada

sandoz canada incorporated - bortezomib (bortezomib mannitol boronic ester) - powder for solution - 3.5mg - bortezomib (bortezomib mannitol boronic ester) 3.5mg - antineoplastic agents

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eugia pharma (malta) ltd. - bortezomib monohydrate 3,664 mg - eq. bortezomib 3,5 mg - powder for solution for injection - 3,5 mg - bortezomib monohydrate 3.664 mg - bortezomib

Canada - English - Health Canada

taro pharmaceuticals inc - bortezomib (bortezomib mannitol boronic ester) - powder for solution - 2.5mg - bortezomib (bortezomib mannitol boronic ester) 2.5mg - antineoplastic agents